Aurora Investment Counsel bought a new position in shares of Bioverativ Inc (NASDAQ:BIVV) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 26,939 shares of the biotechnology company’s stock, valued at approximately $1,453,000.
Several other institutional investors also recently bought and sold shares of the stock. Wells Fargo & Company MN acquired a new stake in Bioverativ during the 3rd quarter valued at $124,500,000. Woodford Investment Management Ltd acquired a new stake in Bioverativ during the 3rd quarter valued at $85,455,000. Jackson Square Partners LLC acquired a new stake in Bioverativ during the 3rd quarter valued at $99,336,000. Old Mutual Global Investors UK Ltd. acquired a new stake in Bioverativ during the 3rd quarter valued at $96,827,000. Finally, ValueAct Holdings L.P. acquired a new stake in Bioverativ during the 3rd quarter valued at $72,514,000. Institutional investors and hedge funds own 95.99% of the company’s stock.
Shares of Bioverativ Inc (NASDAQ:BIVV) opened at $56.09 on Friday. The company has a market capitalization of $6,070.00 and a price-to-earnings ratio of 13.71. Bioverativ Inc has a 52 week low of $40.00 and a 52 week high of $64.41.
Bioverativ (NASDAQ:BIVV) last released its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.25. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The company had revenue of $291.60 million during the quarter, compared to analysts’ expectations of $285.45 million. The firm’s revenue for the quarter was up 27.2% compared to the same quarter last year. equities research analysts anticipate that Bioverativ Inc will post 2.45 EPS for the current year.
A number of equities research analysts recently weighed in on the company. Zacks Investment Research cut Bioverativ from a “buy” rating to a “hold” rating in a report on Wednesday. Deutsche Bank set a $53.00 price target on Bioverativ and gave the company a “hold” rating in a report on Monday, November 20th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $71.00 price target on shares of Bioverativ in a report on Monday, October 23rd. Morgan Stanley reaffirmed an “underweight” rating and set a $47.00 price target (up from $45.00) on shares of Bioverativ in a report on Friday, October 6th. Finally, Argus raised Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a report on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $60.33.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.